Forbes April 15, 2021
Amy Feldman

It’s hard to flawlessly churn out billions of doses of drugs – and we aren’t doing a great job of it. A Midas List VC pulled together a dream team that says it’s come up with a better, faster way.

It’s all come down to Pfizer and Moderna. With Johnson & Johnson’s “one-and-done” shot on pause, America’s race against the virus and its variants now relies on our ability to flawlessly manufacture hundreds of millions of doses of the new mRNA vaccines – at warp speed. And previous quality control issues at a Pfizer plant, on top of Emergent BioSolutions fiasco with the J&J vaccine, are a stark reminder that manufacturing medicine is not easy.

Robert Nelsen, the top biotech...

Today's Sponsors

pCare
Institute for Healthcare Improvement
Crossover Health

Today's Sponsors

Zelis
HealthITq

Today's Sponsor

Holon

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health / COVID
Q&A: Will Perry, Principal, US Cloud Innovation and Engineering Leader, PwC
Blockchain Technology Will Unleash The Power of IoT - And We're Ready to Prove it
The Innovations of Clinical Trials after the Pandemic
Thoughts on Redesigning Health Care: Aligning Incentives to Drive Innovation
CMS Innovation Center Launches New Initiative To Advance Health Equity